SOURCE: Geneart AG

April 30, 2007 13:08 ET

GENEART Receives Patent for Directed Evolution of Proteins

GENEART Granted German Patent for: "Method for Carrying out the Selective Evolution of Proteins in Vitro"; Comparable International Patent Application Is Currently Pending for Europe and North America; The patent Is Vital to the Completion of the BMBF-Funded Network Project for the Evolution of Proteins

REGENSBURG, GERMANY -- (MARKET WIRE) -- April 30, 2007 -- GENEART AG, the world's leading specialist in the production and optimization of synthetic genes, announced today that a patent for the directed evolution of proteins has been granted by the German Patent and Trademark Office ("Deutsches Patent- und Markenamt"). A comparable patent application has been submitted in the PCT phase in several countries throughout Europe and Northern America.

The patent No. DE102005037351 forms an important part of a new technology platform, which is used to significantly improve the efficacy and activity of protein-based therapeutics, vaccines and industrial enzymes. This new technology is comprised of a recursive one-step procedure. In one step, protein variants are continuously synthesized and at the same time screened for improved characteristics. Through this new methodology, GENEART endeavours to yield a large pool of the target protein variants in a shorter time frame. Thus, the one-step method significantly increases the probability of finding a superior fit for the desired variant activity / affinity when compared with the scope of prior conventional multi-step techniques.

The market for these services grows steadily. Today, over $3 billion per year is spent in the U.S. solely for the identification of clinically relevant protein-based therapeutics; and this only covers protein identifications via conventional multi-step procedures in preclinical drug development. This R&D project will open the market for GENEART in the medium term. Successful completion of this project will provide GENEART with the foundation for expanded service offerings in the Gene Evolution sector. The added services will build on newly established gene variants and libraries and encompass protein synthesis and screening.

Legal Information

This document may contain estimates, prognoses and opinions about company plans and objectives, products or services, future results, opinions about these results or opinions leading up to these results. All these projections into the future are subject to risk, uncertainty and unforeseeable change outside the control of the GENEART Group. Many factors may lead to actual results, which considerably deviate from the given projections for these results.


Founded in 1999, GENEART today is the globally leading specialists providing optimized gene solutions to research institutions as well as the pharma, biotech and chemical industries. GENEART offers integrated product systems based on gene synthesis for developing innovative drugs, in particular DNA- and protein-based therapeutics and vaccines, as well as for identifying improved industrial enzymes. The service portfolio ranges from the manufacturing of optimized synthetic genes in accordance with DIN EN ISO 9001:2000 and the generation of gene libraries in combinatorial biology, to the production and development of DNA-based drugs. GENEART, currently a team of more than 100 employees in Regensburg and the subsidiary in Toronto/Canada, reached break even in 2005 and is listed on the German Stock Exchange, Frankfurt, since May 2006.

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information

  • For further inquiries, please contact:
    Bernd Merkl
    Josef-Engert-Str. 11
    D-93053 Regensburg
    Tel.: +49-(0)941-942 76 - 38
    Fax: +49-(0)941-942 76 - 11
    Email Contact

    Frank Ostermair
    Haubrok Investor Relations GmbH
    Maximilianstraße 45
    80538 München
    Tel: +49-(0)89-21027-204
    Fax: +49-(0)89-21027-298
    Email Contact